Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Double-Blind Study of HTD1801 vs Ursodeoxycholic Acid (UDCA) in Adolescents With Primary Sclerosing Cholangitis (PSC)

Trial Profile

A Phase 2, Randomized, Double-Blind Study of HTD1801 vs Ursodeoxycholic Acid (UDCA) in Adolescents With Primary Sclerosing Cholangitis (PSC)

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Dec 2018

At a glance

  • Drugs HTD 1801 (Primary) ; Ursodeoxycholic acid
  • Indications Primary sclerosing cholangitis
  • Focus Therapeutic Use
  • Sponsors HighTide Biopharma
  • Most Recent Events

    • 10 Dec 2018 Planned initiation date changed from 1 Nov 2018 to 1 Mar 2019.
    • 03 Oct 2018 According to a HighTide Therapeutics media release, development of this study were presented at the 2nd Annual Pediatric Autoimmune Liver Disease Symposium and Family Day at Cincinnati Children's Hospital Medical Center (CCHMC).
    • 26 Sep 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top